PRAXIS PRECISION MEDICINES, INC. Earnings Per Share (Diluted)
PRAXIS PRECISION MEDICINES, INC. (PRAX) reported Earnings Per Share (Diluted) of -$2.87 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-08-06
- PRAXIS PRECISION MEDICINES, INC. earnings per share, diluted for the quarter ending 2026-06-30 was -$2.87.
- PRAXIS PRECISION MEDICINES, INC. earnings per share, diluted for the quarter ending 2026-03-31 was -$3.20.
- PRAXIS PRECISION MEDICINES, INC. earnings per share, diluted for the quarter ending 2025-12-31 was -$3.48.
- PRAXIS PRECISION MEDICINES, INC. earnings per share, diluted for the quarter ending 2025-09-30 was -$3.36.
- PRAXIS PRECISION MEDICINES, INC. earnings per share, diluted for fiscal 2025 was -$13.48.
- PRAXIS PRECISION MEDICINES, INC. earnings per share, diluted for fiscal 2024 was -$10.21.
- PRAXIS PRECISION MEDICINES, INC. earnings per share, diluted for fiscal 2023 was -$18.69.
- PRAXIS PRECISION MEDICINES, INC. earnings per share, diluted for fiscal 2022 was -$69.65.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 3 month as first filed | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 6 month as first filed | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 9 month as first filed | Earnings Per Share, Diluted 12 month | Earnings Per Share, Diluted 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$2.87 10-Q · filed 2026-08-06 | -$6.08 10-Q · filed 2026-08-06 | -$9.52 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$12.85 derived: net income ÷ weighted average shares · filed 2026-08-06 | ||||
| 2026-03-31 | -$3.20 10-Q · filed 2026-05-07 | -$6.66 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$10.02 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$13.34 derived: net income ÷ weighted average shares · filed 2026-08-06 | ||||
| 2025-12-31 | -$3.48 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$6.85 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$10.17 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$13.48 10-K · filed 2026-02-19 | ||||
| 2025-09-30 | -$3.36 10-Q · filed 2025-11-05 | -$6.68 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$9.97 10-Q · filed 2025-11-05 | -$12.92 derived: net income ÷ weighted average shares · filed 2026-08-06 | ||||
| 2025-06-30 | -$3.31 10-Q · filed 2026-08-06 | -$6.60 10-Q · filed 2026-08-06 | -$9.55 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$12.33 derived: net income ÷ weighted average shares · filed 2026-08-06 | ||||
| 2025-03-31 | -$3.29 10-Q · filed 2026-05-07 | -$6.23 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$9.00 derived: net income ÷ weighted average shares · filed 2026-08-06 | -$10.80 derived: net income ÷ weighted average shares · filed 2026-08-06 | ||||
| 2024-12-31 | -$2.93 derived: net income ÷ weighted average shares · filed 2026-02-19 | -$5.69 derived: net income ÷ weighted average shares · filed 2026-02-19 | -$7.45 derived: net income ÷ weighted average shares · filed 2026-02-19 | -$10.21 10-K · filed 2026-02-19 | ||||
| 2024-09-30 | -$2.75 10-Q · filed 2025-11-05 | -$4.49 derived: net income ÷ weighted average shares · filed 2025-11-05 | -$7.21 10-Q · filed 2025-11-05 | -$9.95 derived: net income ÷ weighted average shares · filed 2026-02-19 | ||||
| 2024-06-30 | -$1.74 10-Q · filed 2025-08-04 | -$4.41 10-Q · filed 2025-08-04 | -$7.11 derived: net income ÷ weighted average shares · filed 2026-02-19 | -$9.73 derived: net income ÷ weighted average shares · filed 2026-02-19 | ||||
| 2024-03-31 | -$2.84 10-Q · filed 2025-05-02 | -$5.78 derived: net income ÷ weighted average shares · filed 2026-02-19 | -$8.53 derived: net income ÷ weighted average shares · filed 2026-02-19 | -$13.67 derived: net income ÷ weighted average shares · filed 2026-02-19 | ||||
| 2023-12-31 | -$2.96 derived: net income ÷ weighted average shares · filed 2026-02-19 | -$5.68 derived: net income ÷ weighted average shares · filed 2026-02-19 | -$11.30 derived: net income ÷ weighted average shares · filed 2026-02-19 | -$18.69 10-K · filed 2026-02-19 | ||||
| 2023-09-30 | -$2.72 10-Q · filed 2024-11-06 | -$0.18 10-Q · filed 2023-11-07 | -$8.61 derived: net income ÷ weighted average shares · filed 2025-02-28 | -$16.73 10-Q · filed 2024-11-06 | -$1.12 10-Q · filed 2023-11-07 | $5.13 derived: net income ÷ weighted average shares · filed 2025-02-28 | ||
| 2023-06-30 | -$7.38 10-Q · filed 2024-08-13 | -$0.49 10-Q · filed 2023-08-09 | -$17.51 10-Q · filed 2024-08-13 | -$1.17 10-Q · filed 2023-08-09 | $2.91 derived: net income ÷ weighted average shares · filed 2025-02-28 | $8.90 derived: net income ÷ weighted average shares · filed 2025-02-28 | ||
| 2023-03-31 | -$10.58 10-Q · filed 2024-05-13 | -$0.71 10-Q · filed 2023-05-11 | $1.30 derived: net income ÷ weighted average shares · filed 2025-02-28 | $4.89 derived: net income ÷ weighted average shares · filed 2025-02-28 | $24.68 derived: net income ÷ weighted average shares · filed 2025-02-28 | |||
| 2022-12-31 | $0.33 derived: net income ÷ weighted average shares · filed 2024-03-05 | $2.16 derived: net income ÷ weighted average shares · filed 2024-03-05 | $13.14 derived: net income ÷ weighted average shares · filed 2024-03-05 | -$69.65 10-K · filed 2024-03-05 | -$4.64 10-K · filed 2023-02-07 | |||
| 2022-09-30 | -$0.96 10-Q · filed 2023-11-07 | -$2.28 derived: net income ÷ weighted average shares · filed 2024-03-05 | -$3.79 10-Q · filed 2023-11-07 | -$5.09 derived: net income ÷ weighted average shares · filed 2024-03-05 | ||||
| 2022-06-30 | -$1.32 10-Q · filed 2023-08-09 | -$2.83 10-Q · filed 2023-08-09 | -$4.14 derived: net income ÷ weighted average shares · filed 2024-03-05 | -$5.14 derived: net income ÷ weighted average shares · filed 2024-03-05 | ||||
| 2022-03-31 | -$1.51 10-Q · filed 2023-05-11 | -$2.81 derived: net income ÷ weighted average shares · filed 2024-03-05 | -$3.82 derived: net income ÷ weighted average shares · filed 2024-03-05 | -$4.72 derived: net income ÷ weighted average shares · filed 2024-03-05 | ||||
| 2021-12-31 | -$1.30 derived: net income ÷ weighted average shares · filed 2023-02-07 | -$2.30 derived: net income ÷ weighted average shares · filed 2023-02-07 | -$3.19 derived: net income ÷ weighted average shares · filed 2023-02-07 | -$3.94 10-K · filed 2023-02-07 | ||||
| 2021-09-30 | -$1.00 10-Q · filed 2022-11-09 | -$1.88 derived: net income ÷ weighted average shares · filed 2023-02-07 | -$2.61 10-Q · filed 2022-11-09 | -$3.45 derived: net income ÷ weighted average shares · filed 2023-02-07 | ||||
| 2021-06-30 | -$0.88 10-Q · filed 2022-08-08 | -$1.59 10-Q · filed 2022-08-08 | -$2.42 derived: net income ÷ weighted average shares · filed 2023-02-07 | -$3.76 derived: net income ÷ weighted average shares · filed 2023-02-07 | ||||
| 2021-03-31 | -$0.71 10-Q · filed 2022-05-09 | -$1.53 derived: net income ÷ weighted average shares · filed 2023-02-07 | -$2.93 derived: net income ÷ weighted average shares · filed 2023-02-07 | -$4.45 derived: net income ÷ weighted average shares · filed 2023-02-07 | ||||
| 2020-12-31 | -$0.83 derived: net income ÷ weighted average shares · filed 2022-02-28 | -$2.58 derived: net income ÷ weighted average shares · filed 2022-02-28 | -$4.70 derived: net income ÷ weighted average shares · filed 2022-02-28 | -$7.86 10-K · filed 2022-02-28 | ||||
| 2020-09-30 | -$12.10 10-Q · filed 2021-11-03 | -$16.80 derived: net income ÷ weighted average shares · filed 2022-02-28 | -$26.53 10-Q · filed 2021-11-03 | |||||
| 2020-06-30 | -$8.28 10-Q · filed 2021-08-16 | -$14.37 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |